ENERGENESIS BIOMEDICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.6 TWD | +1.09% |
|
+3.73% | -7.95% |
| 04-08 | Energenesis Biomedical CO.,LTD. announced a financing transaction | CI |
| 02-29 | Energenesis Biomedical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 7.35M 225K 309K | Sales 2023 | 7.16M 220K 301K | Capitalization | 4.59B 141M 193M |
|---|---|---|---|---|---|
| Net income 2022 | -266M -8.16M -11.2M | Net income 2023 | -260M -7.97M -10.94M | EV / Sales 2022 | 324 x |
| Net cash position 2022 | 475M 14.57M 20M | Net cash position 2023 | 691M 21.19M 29.08M | EV / Sales 2023 | 545 x |
| P/E ratio 2022 |
-10.7
x | P/E ratio 2023 |
-16.7
x | Employees | 35 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.22% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.09% | ||
| 1 week | +3.73% | ||
| Current month | -5.44% | ||
| 1 month | -5.44% | ||
| 3 months | -9.45% | ||
| 6 months | -14.20% | ||
| Current year | -7.95% |
1 week
53.50
57.10
1 month
51.5063.90
Current year
51.5063.90
1 year
51.5099.50
3 years
30.9099.50
5 years
30.90102.00
10 years
28.51102.00
| Managers | Title | Age | Since |
|---|---|---|---|
Han Min Chen
FOU | Founder | - | 12-08-27 |
Pei Chao Chen
DFI | Director of Finance/CFO | - | 20-05-24 |
Yi-fang Cheng
CTO | Chief Tech/Sci/R&D Officer | - | 13-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shou Shan Wu
BRD | Director/Board Member | 74 | 19-05-05 |
Jen Yi Chiu
FOU | Founder | - | 12-08-27 |
Han Min Chen
FOU | Founder | - | 12-08-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 55.6 | +1.09% | 99 491 |
| 24-04-29 | 55 | +0.36% | 81,176 |
| 24-04-26 | 54.8 | +0.74% | 145,770 |
| 24-04-25 | 54.4 | -0.91% | 83,306 |
| 24-04-24 | 54.9 | +0.55% | 72,673 |
End-of-day quote Taiwan S.E., April 29, 2024
More quotes
ENERGENESIS BIOMEDICAL CO., LTD. is mainly engaged in the research and development of new drugs. The Company's main product projects include experimental service analysis and reagent sales. The Company's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.95% | 128M | |
| +0.93% | 42.86B | |
| +13.70% | 42.74B | |
| +44.81% | 41.36B | |
| -6.20% | 27.68B | |
| +6.89% | 25.15B | |
| -23.34% | 18.63B | |
| +29.72% | 12.37B | |
| -2.92% | 11.92B | |
| +7.05% | 11.21B |
- Stock Market
- Equities
- 6657 Stock
